Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis

Yamamura, Jun; Masuda, Norikazu; Yasojima, Hiroyuki; Mizutani, Masaki; Kuriyama, Kinya; Nakamori, Shoji; Sekimoto, Mitsugu; Mano, Masayuki; Tanaka, Eiichi; Nonaka, Masahiro

doi:10.1159/000442192

Cited by 7 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional prognostic factors include age, menopausal status, status of axillary lymph nodes, tumor size, histological features, and estrogen and progesterone receptors (6), and the prognosis of breast cancer is closely associated with the invasion and metastasis early on. It is reported that peritoneal metastases (7,8), lymph node metastasis (9,10) and brain metastasis (11)(12)(13) in breast cancer are usually associated with a poor prognosis following standard treatments. The progression, invasion and metastasis of breast cancer involve multiple genetic mutations, leading to the activation of oncogenes and the inactivation of tumor suppressor genes (14,15).…”

Section: Introductionmentioning

confidence: 99%

Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the β‑catenin signaling pathway

Lai

Lin

et al. 2017

Mol Med Report

View full text Add to dashboard Cite

Breast cancer is one of the most common types of carcinoma in humans. The aim of the present study was to identify the role of Notch 1 in the proliferation and invasion of human breast cancer cells. Firstly, the levels of Notch 1 were determined by western blot analysis in breast cancer cell lines, and the results revealed that the expression levels of Notch 1 were markedly higher in MDA‑MB‑231 and MCF‑7 cells, and lower in MCF‑10A cells, compared with human mammary epithelial cells. An MTT assay was used to determine the viability of breast cancer cells. The optical density (OD)490 values were significantly decreased in Notch 1 short hairpin (sh)RNA‑transfected MCF‑7 and MDA‑MB‑231 cells, compared with the OD490 values in the negative control shRNA‑transfected cells. The MCF‑7 cells and MDA‑MB‑231 cells were also treated with increasing concentrations of MRK003, a Notch 1 inhibitor, for 24, 48 and 72 h, respectively. The inhibition rate was gradually increased in the MRK003‑treated cells in a time‑ and dose‑dependent manner. The invasive ability of the cells was determined using a Transwell migration assay. The migration ability was significantly decreased in the Notch 1‑transfected MCF‑7 cells and MDA‑MB‑231 cells. The molecular mechanism was examined, and the knockdown of Notch 1 significantly decreased the expression levels of β‑catenin, matrix metalloproteinase (MMP)‑2 and MMP‑9, and was also correlated with the downregulation of β‑catenin in the nucleus. In conclusion, Notch 1 was key in the progression of breast cancer, and knocking down the expression of Notch 1 significantly suppressed the proliferation and invasion of breast cancer cells. This provides novel clues for cancer therapy in human breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the β‑catenin signaling pathway

Lai

Lin

et al. 2017

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Patients with HER2 positive lived longer than those with negative HER2 (median time 11 vs. 6 months). Yamamura et al ( 20 ) conducted research into 75 early BC patients subsequently developing brain metastasis. The results indicated that luminal HER2 cancer, favorable PS and single metastatic brain tumor independently affected the prognosis of those patients.…”

Section: Resultsmentioning

confidence: 99%

“…Referring to the efficacy, there are various outcomes in different studies in this review. It could be found in some studies that adjuvant therapies, including chemotherapy, endocrine therapy, targeted therapy and radiotherapy, could prolong the survival time of patients with MBC, while there still are some studies not revealing the significant benefits on survival from systemic treatment (1,2,7,8,(18)(19)(20)(21)24). However, due to the fact that most studies included are single-center studies, it is inevitable for the existence of patient selection bias, which would disturb the results.…”

Section: Discussionmentioning

confidence: 99%

“…Among them, there was 1 study identifying patients diagnosed with bone as only metastasis site (13) and were 2 studies focusing on human epidermal growth factor receptor 2 oncogene (HER2) positive patients (11,14). There were 10 studies focusing on BC patients with metastatic recurrence (1,2,7,9,(16)(17)(18)(19)(20)(21), in which there was 1 study focusing on bone metastasis (BM) ( 16), 1 study focusing on central nervous system (CNS) metastasis ( 17), 1 study focusing on brain metastasis (20) and 1 study focusing on patients older than 70 years old, respectively (19). There were 3 studies including patients diagnosed with PMBC (22)(23)(24), in which there was 1 study focusing on hormone receptor (HR) positive patients.…”

Section: Selection and Characteristics Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors for patients with metastatic breast cancer: a literature review

Hu¹,

Shao²,

Ran³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: To treat metastatic breast cancer (MBC) more precisely, many efforts have been made to identify prognostic factors of MBC in many studies. This review aims to qualitatively summarize these studies and to provide a reference for the research of MBC.Methods: Relevant papers were searched on PubMed, with the search terms including MBC, prognostic factors and prognosis, and the studies aimed at exploring prognostic factors for patients with histologically confirmed MBC, including stage IV at initial diagnosis and metastatic recurrence, were included.Results: A total of 30 papers were included at last. An analysis of prognostic factors frome those studies was conducted. Age at primary diagnosis (6 studies), performance status (4 studies), histological grade (4 studies), hormonal receptor (HR) status (9 studies) and site of metastasis (12 studies) were universally acknowledged prognostic factors. There were four studies revealing that short DFS was significantly associated with better OS, while there was one study not revealing this association. There were various results in different studies with a reference to efficacy. Surgery and endocrine therapy were related to a better prognosis (3 studies).Targeted therapies could also conduce to the prognosis. However, there was still a contention on the role of radiotherapy. In particular, a model was brought out to calculate the risk of death in MBC. Meanwhile, it was found that some biomarkers are related to prognosis as well as per the latest findings in some studies.Conclusions: In summary, intrinsic characteristics of tumors such as HR status and histological grade are the main factors affecting the prognosis of patients with MBC. Besides traditional factors, some new drugs and biomarkers are also associated with the prognosis of patients with MBC. In the future, the focus of studies shall be on the construction of a practical and high-quality model to predict the risk of death in MBC patients.

show abstract

“…Evidence indicates that breast cancer patients with brain metastasis (BM) have a very poor prognosis and a short survival time following BM [9]. However, much progress has been made regarding the diagnosis of the condition, especially with the application of PET-CT and MRI [10].…”

Section: Discussionmentioning

confidence: 99%

Screening and identification of key biomarkers in breast cancer with brain metastasis: Evidence from bioinformatic analysis

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose. Breast cancer (BC) has a poor prognosis when brain metastases (BM) occur, and the treatment effect is limited. In this study, we aim to identify representative candidate biomarkers for clinical prognosis of patients with BM and explore the mechanisms underlying the progression of BC.Methods. Herein, we examined the Microarray datasets (GSE125989) obtained from the Gene Expression Omnibus database to find the target genes in BC patients with BM. We employed the GEO2R tool to filter the differentially expressed genes (DEGs) that participate in primary BC and BC with BM. Subsequently, using the DAVID tool, we conducted an enrichment analysis with the screened DEGs based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) functional annotation. The STRING database was employed to analyze the protein-protein interactions of the DEGs and visualized using Cytoscape software. Lastly, the Kaplan-Meier plotter database was employed to determine the prognostic potential of hub genes in BC.Results. We screened out 311 upregulated DEGs and 104 downregulated DEGs. The enrichment analyses revealed that all the DEGs were` enriched in the biological process of extracellular matrix organization, cell adhesion, proteolysis, collagen catabolic process and immune response. The significant enrichment pathways were focal adhesion, protein absorption and digestion, ECM-receptor interaction, PI3K-Akt signalling pathway, and Pathways in cancer. The top ten hub nodes screened out included FN1, VEGFA, COL1A1, MMP2, COL3A1, COL1A2, POSTN, DCN, BGN and LOX. The Kaplan-Meier plotter results showed that the three hub genes (FN1, VEGFA and DCN) are candidate biomarkers for clinical prognosis of patients with BM.Conclusion. we identified seven genes related to poor prognosis in BCBM. FN1, VEGFA and DCN can be considered as potential prognostic markers for BCBM. Meantime, COL1A1, POSTN, BGN and LOX may be linked to the distant transformation of BC.

show abstract

Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis

Cited by 7 publications

References 29 publications

Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the β‑catenin signaling pathway

Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the β‑catenin signaling pathway

Prognostic factors for patients with metastatic breast cancer: a literature review

Screening and identification of key biomarkers in breast cancer with brain metastasis: Evidence from bioinformatic analysis

Contact Info

Product

Resources

About